|Table of Contents|

Research progress of m6A-RNA methylated YTHDF1 binding protein in glioma

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2023 13
Page:
2512-2518
Research Field:
Publishing date:

Info

Title:
Research progress of m6A-RNA methylated YTHDF1 binding protein in glioma
Author(s):
ZHU LinYU TaoZHENG FakangGONG Haidong
Department of Neurosurgery,Hongqi Hospital Affiliated to Mudanjiang Medical College,Heilongjiang Mudanjiang 157011,China.
Keywords:
YTHDF1gliomam6A methylationcancer stem cells
PACS:
R739.41
DOI:
10.3969/j.issn.1672-4992.2023.13.027
Abstract:
Glioma is the most common primary intracranial malignant tumor,accounting for 45% of brain tumors.Currently,gliomas are mainly treated by surgery,but their infiltration growth and high recurrence rate lead to poor prognosis.At present,RNA modification,especially m6A methylation,is a hot spot in tumor research.With the continuous progress of high-throughput sequencing methods,the research on transcriptional epigenetics is also deepening.m6A (N6-methyladenosine) methylation is the most common modification in eukaryotic cells,especially in messenger RNA (message ribonucleic acid,mRNA).m6A methylation can affect the metabolism of RNA from many aspects such as RNA transcription,nuclear export,translation,decay,etc.It participates in the embryonic development of organisms,circadian rhythm,stress response,and even the occurrence of tumors.YTHDF1,the highest expression of m6A methylated recognition protein in glioma can recognize and induce target translation.This article will combine recent research progress,focusing on the mode of action,biological characteristics,development of gliomas,and existing potential effects of the m6A binding protein YTHDF1.

References:

[1]CHEN R,SMITH-COHN M,COHEN AL,et al.Glioma subclassifications and their clinical significance[J].Neurotherapeutics,2017,14(2):284-297.
[2]LE RHUN E,PREUSSER M,ROTH P,et al.Molecular targeted therapy of glioblastoma[J].Cancer Treat Rev,2019,80:101896.
[3]OBERHEIM BUSH NA,HERVEY-JUMPER SL,BERGER MS.Management of glioblastoma,present and future[J].World Neurosurg,2019,131:328-338.
[4]JACKSON CM,CHOI J,LIM M.Mechanisms of immunotherapy resistance:lessons from glioblastoma[J].Nat Immunol,2019,20(9):1100-1109.
[5]BOCCALETTO P,MACHNICKA MA,PURTA E,et al.MODOMICS:a database of RNA modification pathways.2017 update[J].Nucleic Acids Res,2018,46(D1):D303-D307.
[6]YUE Y,LIU J,HE C.RNA N6-methyladenosine methylation in post-transcriptional gene expression regulation[J].Genes Dev,2015,29(13):1343-1355.
[7]DESROSIERS R,FRIDERICI K,ROTTMAN F.Identification of methylated nucleosides in messenger RNA from Novikoff hepatoma cells[J].Proc Natl Acad Sci USA,1974,71(10):3971-3975.
[8]JONKHOUT N,TRAN J,SMITH MA,et al.The RNA modification landscape in human disease[J].Rna,2017,23(12):1754-1769.
[9]FRYE M,HARADA BT,BEHM M,et al.RNA modifications modulate gene expression during development[J].Science,2018,361(6409):1346-1349.
[10]KARTHIYA R,KHANDELIA P.m6A RNA methylation:Ramifications for gene expression and human health[J].Mol Biotechnol,2020,62(10):467-484.
[11]LIU ZX,LI LM,SUN HL,et al.Link between m6A modification and cancers[J].Front Bioeng Biotechnol,2018,6:89.
[12]SUN T,WU R,MING L.The role of m6A RNA methylation in cancer[J].Biomed Pharmacother,2019,112:108613.
[13]YANG Y,HSU PJ,CHEN YS,et al.Dynamic transcriptomic m(6)A decoration:writers,erasers,readers and functions in RNA metabolism[J].Cell Res,2018,28(6):616-624.
[14]ZHANG Y,GENG X,LI Q,et al.m6A modification in RNA:biogenesis,functions and roles in gliomas[J].J Exp Clin Cancer Res,2020,39(1):192.
[15]QU S,CHEN Z,LIU B,et al.N6-methyladenine-related genes affect biological behavior and the prognosis of glioma[J].Cancer Med,2021,10(1):98-108.
[16]ZHENG W,DONG X,ZHAO Y,et al.Multiple functions and mechanisms underlying the role of METTL3 in human cancers[J].Front Oncol,2019,9:1403.
[17]ZENG C,HUANG W,LI Y,et al.Roles of METTL3 in cancer:mechanisms and therapeutic targeting[J].J Hematol Oncol,2020,13(1):117.
[18]CHOE J,LIN S,ZHANG W,et al.mRNA circularization by METTL3-eIF3h enhances translation and promotes oncogenesis[J].Nature,2018,561(7724):556-560.
[19]JIN D,GUO J,WU Y,et al.m(6)A mRNA methylation initiated by METTL3 directly promotes YAP translation and increases YAP activity by regulating the MALAT1-miR-1914-3p-YAP axis to induce NSCLC drug resistance and metastasis[J].J Hematol Oncol,2019,12(1):135.
[20]WANG P,DOXTADER KA,NAM Y.Structural basis for cooperative function of Mettl3 and Mettl14 methyltransferases[J].Mol Cell,2016,63(2):306-317.
[21]MA L,HUA RX,LIN H,et al.The contribution of WTAP gene variants to Wilms tumor susceptibility[J].Gene,2020,754:144839.
[22]PING XL,SUN BF,WANG L,et al.Mammalian WTAP is a regulatory subunit of the RNA N6-methyladenosine methyltransferase[J].Cell Res,2014,24(2):177-189.
[23]LAN T,LI H,ZHANG D,et al.KIAA1429 contributes to liver cancer progression through N6-methyladenosine-dependent post-transcriptional modification of GATA3[J].Mol Cancer,2019,18(1):186.
[24]WANG T,KONG S,TAO M,et al.The potential role of RNA N6-methyladenosine in cancer progression[J].Mol Cancer,2020,19(1):88.
[25]KNUCKLES P,LENCE T,HAUSSMANN IU,et al.Zc3h13/Flacc is required for adenosine methylation by bridging the mRNA-binding factor Rbm15/Spenito to the m(6)A machinery component Wtap/Fl(2)d[J].Genes Dev,2018,32(5-6):415-429.
[26]WEN J,LYU R,MA H,et al.Zc3h13 regulates nuclear RNA m(6)A methylation and mouse embryonic stem cell self-renewal[J].Mol Cell,2018,69(6):1028-1038.
[27]ZHAO W,QI X,LIU L,et al.Epigenetic regulation of m(6)A modifications in human cancer[J].Mol Ther Nucleic Acids,2020,19:405-412.
[28]YUE Y,LIU J,CUI X,et al.VIRMA mediates preferential m(6)A mRNA methylation in 3' UTR and near stop codon and associates with alternative polyadenylation[J].Cell Discov,2018,4:10.
[29]LI J,HAN Y,ZHANG H,et al.The m6A demethylase FTO promotes the growth of lung cancer cells by regulating the m6A level of USP7 mRNA[J].Biochem Biophys Res Commun,2019,512(3):479-485.
[30]NIU Y,ZHAO X,WU YS,et al.N6-methyl-adenosine (m6A) in RNA:an old modification with a novel epigenetic function[J].Genomics Proteomics Bioinformatics,2013,11(1):8-17.
[31]WANG J,WANG J,GU Q,et al.The biological function of m6A demethylase ALKBH5 and its role in human disease[J].Cancer Cell Int,2020,20:347.
[32]YU H,YANG X,TANG J,et al.ALKBH5 inhibited cell proliferation and sensitized bladder cancer cells to cisplatin by m6A-CK2α-mediated glycolysis[J].Mol Ther Nucleic Acids,2021,23:27-41.
[33]REICHEL M,KSTER T,STAIGER D.Marking RNA:m6A writers,readers,and functions in Arabidopsis[J].J Mol Cell Biol,2019,11(10):899-910.
[34]PATIL DP,CHEN CK,PICKERING BF,et al.m(6)A RNA methylation promotes XIST-mediated transcriptional repression[J].Nature,2016,537(7620):369-373.
[35]ANITA R,PARAMASIVAM A,PRIYADHARSINI JV,et al.The m6A readers YTHDF1 and YTHDF3 aberrations associated with metastasis and predict poor prognosis in breast cancer patients[J].Am J Cancer Res,2020,10(8):2546-2554.
[36]HE L,LI H,WU A,et al.Functions of N6-methyladenosine and its role in cancer[J].Mol Cancer,2019,18(1):176.
[37]MEYER KD,JAFFREY SR.Rethinking m(6)A readers,writers,and erasers[J].Annu Rev Cell Dev Biol,2017,33:319-342.
[38]SHI H,WEI J,HE C.Where,when,and how:Context-dependent functions of RNA methylation writers,readers,and erasers[J].Mol Cell,2019,74(4):640-650.
[39]CHANG G,SHI L,YE Y,et al.YTHDF3 induces the translation of m(6)A-enriched gene transcripts to promote breast cancer brain metastasis[J].Cancer Cell,2020,38(6):857-871.
[40]LIU N,DAI Q,ZHENG G,et al.N(6)-methyladenosine-dependent RNA structural switches regulate RNA-protein interactions[J].Nature,2015,518(7540):560-564.
[41]ALARCON CR,GOODARZI H,LEE H,et al.HNRNPA2B1 is a mediator of m(6)A-dependent nuclear RNA processing events[J].Cell,2015,162(6):1299-1308.
[42]HUANG H,WENG H,SUN W,et al.Recognition of RNA N(6)-methyladenosine by IGF2BP proteins enhances mRNA stability and translation[J].Nat Cell Biol,2018,20(3):285-295.
[43]SHI H,WANG X,LU Z,et al.YTHDF3 facilitates translation and decay of N(6)-methyladenosine-modified RNA[J].Cell Res,2017,27(3):315-328.
[44]CATE JH.Human eIF3:from 'blobology' to biological insight[J].Philos Trans R Soc Lond B Biol Sci,2017,372(1716):20160176.
[45]LIU S,LI G,LI Q,et al.The roles and mechanisms of YTH domain-containing proteins in cancer development and progression[J].Am J Cancer Res,2020,10(4):1068-1084.
[46]LIU T,WEI Q,JIN J,et al.The m6A reader YTHDF1 promotes ovarian cancer progression via augmenting EIF3C translation[J].Nucleic Acids Res,2020,48(7):3816-3831.
[47]OROUJI E,PEITSCH WK,OROUJI A,et al.Oncogenic role of an epigenetic reader of m(6)A RNA modification:YTHDF1 in merkel cell carcinoma[J].Cancers(Basel),2020,12(1):202.
[48]YARMISHYN AA,YANG YP,LU KH,et al.Musashi-1 promotes cancer stem cell properties of glioblastoma cells via upregulation of YTHDF1[J].Cancer Cell Int,2020,20(1):597.
[49]PAN S,WU W,REN F,et al.MiR-346-5p promotes colorectal cancer cell proliferation in vitro and in vivo by targeting FBXL2 and activating the β-catenin signaling pathway[J].Life Sci,2020,244:117300.
[50]LI Y,XU J,ZHANG J,et al.MicroRNA-346 inhibits the growth of glioma by directly targeting NFIB[J].Cancer Cell Int,2019,19:294.
[51]XU C,YUAN B,HE T,et al.Prognostic values of YTHDF1 regulated negatively by miR-3436 in glioma[J].J Cell Mol Med,2020,24(13):7538-7549.
[52]杨蕊,朱奕,王颖,等.丙酮酸脱氢酶激酶PDK4在临床中的研究进展[J].中国医院药学杂志,2019,39(01):101-105. YANG R,ZHU Y,WANG Y,et al.Research progress of pyruvate dehydrogenase kinase PDK4 in clinic[J].Chin J Hosp Pharm,2019,39(01):101-105.
[53]LI Z,PENG Y,LI J,et al.N(6)-methyladenosine regulates glycolysis of cancer cells through PDK4[J].Nat Commun,2020,11(1):2578.
[54]DIXIT D,AHMAD F,GHILDIYAL R,et al.CK2 inhibition induced PDK4-AMPK axis regulates metabolic adaptation and survival responses in glioma[J].Exp Cell Res,2016,344(1):132-142.
[55]HOSONO Y,NIKNAFS YS,PRENSNER JR,et al.Oncogenic role of THOR,a conserved cancer/testis long non-coding RNA[J].Cell,2017,171(7):1559-1572.
[56]XUE J,ZHONG S,SUN BM,et al.Lnc-THOR silencing inhibits human glioma cell survival by activating MAGEA6-AMPK signaling[J].Cell Death Dis,2019,10(11):866.
[57]LIU H,XU Y,YAO B,et al.A novel N6-methyladenosine (m6A)-dependent fate decision for the lncRNA THOR[J].Cell Death Dis,2020,11(8):613.
[58]PI J,WANG W,JI M,et al.YTHDF1 promotes gastric carcinogenesis by controlling translation of FZD7[J].Cancer Res,2021,81(10):2651-2665.
[59]QIU X,JIAO J,LI Y,et al.Overexpression of FZD7 promotes glioma cell proliferation by upregulating TAZ[J].Oncotarget,2016,7(52):85987-85999.
[60]LIU Q,GUAN Y,LI Z,et al.miR-504 suppresses mesenchymal phenotype of glioblastoma by directly targeting the FZD7-mediated Wnt-β-catenin pathway[J].J Exp Clin Cancer Res,2019,38(1):358.
[61]刘德仁,丁闯,侍孝红,等.c-Myc在人胃癌组织中的表达及其对胃癌细胞增殖、迁移和侵袭的影响[J].现代肿瘤医学,2021,29(20):3526-3531. LIU DR,DING C,SHI XH,et al.Expression of c-Myc in human gastric cancer tissues and its effect on proliferation,migration and invasion of gastric cancer cells[J].Modern Oncology,2021,29(20):3526-3531.
[62]WANG J,WANG H,LI Z,et al.c-Myc is required for maintenance of glioma cancer stem cells[J].PLoS One,2008,3(11):e3769.
[63]NISHIZAWA Y,KONNO M,ASAI A,et al.Oncogene c-Myc promotes epitranscriptome m(6)A reader YTHDF1 expression in colorectal cancer[J].Oncotarget,2018,9(7):7476-7486.
[64]LIU X,QIN J,GAO T,et al.YTHDF1 facilitates the progression of hepatocellular carcinoma by promoting FZD5 mRNA translation in an m6A-dependent manner[J].Mol Ther Nucleic Acids,2020,22:750-765.
[65]TANG R,ZHANG Y,LIANG C,et al.The role of m6A-related genes in the prognosis and immune microenvironment of pancreatic adenocarcinoma[J].PeerJ,2020,8:e9602.
[66]HAN D,LIU J,CHEN C,et al.Author correction:Anti-tumour immunity controlled through mRNA m(6)A methylation and YTHDF1 in dendritic cells[J].Nature,2019,568(7751):E3.
[67]CHEN PY,WU CY,FANG JH,et al.Functional change of effector tumor-infiltrating CCR5(+)CD38(+)HLA-DR(+)CD8(+) T cells in glioma microenvironment[J].Front Immunol,2019,10:2395.
[68]SHI Y,FAN S,WU M,et al.YTHDF1 links hypoxia adaptation and non-small cell lung cancer progression[J].Nat Commun,2019,10(1):4892.
[69]LIU X,CHEN J,LI W,et al.Inhibition of casein kinase II by CX-4945,but not Yes-associated protein(YAP) by verteporfin,enhances the antitumor efficacy of temozolomide in glioblastoma[J].Transl Oncol,2020,13(1):70-78.
[70]LIU T,XU H,HUANG M,et al.Circulating glioma cells exhibit stem cell-like properties[J].Cancer Res,2018,78(23):6632-6642.

Memo

Memo:
黑龙江省省属基本科研业务费(编号:2020-KYYWF-0751)
Last Update: 2023-05-31